Catastrophic Antiphospholipid Syndrome

Area of Science:

• Immunology
• Hematology
• Rheumatology

Background:

• Catastrophic Antiphospholipid Syndrome (CAPS) is a rare, life-threatening condition characterized by widespread microthrombosis.
• Unlike classic Antiphospholipid Syndrome (APS), CAPS involves a severe inflammatory response termed a "thrombotic storm."
• CAPS often presents following infection, trauma, or surgery, with symptoms including fever, thrombocytopenia, and multi-organ failure.

Purpose of the Study:

• To highlight the diagnostic challenges in CAPS, particularly the fluctuating antiphospholipid antibody levels.
• To outline current therapeutic strategies for managing CAPS.
• To emphasize the need for improved clinical protocols and medical education for better patient outcomes.

Main Methods:

• Review of clinical presentation and diagnostic criteria for CAPS.
• Analysis of current treatment modalities, including triple therapy (anticoagulants, plasmapheresis, glucocorticosteroids) and LMWH.
• Discussion of the multifactorial nature and management complexities of CAPS.

Main Results:

• Antiphospholipid antibody levels can fluctuate, complicating CAPS diagnosis.
• Triple therapy is a common treatment, with LMWH recommended for its anti-inflammatory and anticoagulant properties.
• Effective management requires an interdisciplinary approach, timely diagnosis, and preventative strategies.

Conclusions:

• CAPS necessitates specialized medical care and timely diagnosis to mitigate severe consequences.
• Enhanced clinical protocols and education are vital for improving therapeutic approaches and reducing CAPS-related mortality.
• Early recognition and management are key to addressing the "thrombotic storm" characteristic of CAPS.